National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

recombinant adenovirus-L523S vaccine
A replication-defective adenovirus containing a gene that encodes the human protein L523S with potential antineoplastic activity. Upon administration, recombinant adenovirus-L523S vaccine expresses L523S, which may stimulate antibody and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing L523S. L523S is an RNA-binding protein that belongs to the KOC (K homology domain containing protein over-expressed in cancer) family of proteins. As an oncofetal protein, L523S is normally expressed in early embryonic tissues and certain normal adult tissues such as colon, fallopian tube, gall bladder, and ovary tissues but may be overexpressed in squamous cell cancers of the lung. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Abbreviation:Ad/L523S



Previous:Rebif, Recentin, recombinant 70-kD heat-shock protein, recombinant adenovirus-hIFN-beta, recombinant adenovirus-interferon SCH 721015
Next:recombinant adenovirus-p53 SCH-58500, recombinant bispecific single-chain antibody rM28, recombinant CD40-ligand, recombinant dHER2 vaccine, recombinant flt3 ligand

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov